SG11202109003QA - Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer - Google Patents

Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer

Info

Publication number
SG11202109003QA
SG11202109003QA SG11202109003QA SG11202109003QA SG11202109003QA SG 11202109003Q A SG11202109003Q A SG 11202109003QA SG 11202109003Q A SG11202109003Q A SG 11202109003QA SG 11202109003Q A SG11202109003Q A SG 11202109003QA SG 11202109003Q A SG11202109003Q A SG 11202109003QA
Authority
SG
Singapore
Prior art keywords
treating cancer
pathway inhibitors
enhanced efficacy
efficacy
enhanced
Prior art date
Application number
SG11202109003QA
Inventor
Caroline Liot
Frank Kuhnert
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202109003QA publication Critical patent/SG11202109003QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202109003QA 2019-03-06 2020-02-28 Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer SG11202109003QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814648P 2019-03-06 2019-03-06
US202062966760P 2020-01-28 2020-01-28
PCT/US2020/020494 WO2020180727A1 (en) 2019-03-06 2020-02-28 Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer

Publications (1)

Publication Number Publication Date
SG11202109003QA true SG11202109003QA (en) 2021-09-29

Family

ID=70009429

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109003QA SG11202109003QA (en) 2019-03-06 2020-02-28 Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer

Country Status (13)

Country Link
US (1) US20200283518A1 (en)
EP (1) EP3935085A1 (en)
JP (1) JP7548924B2 (en)
KR (1) KR20210136071A (en)
CN (1) CN113677707A (en)
AU (1) AU2020231343A1 (en)
CA (1) CA3129963A1 (en)
IL (1) IL285525A (en)
MA (1) MA55204A (en)
MX (1) MX2021010560A (en)
SG (1) SG11202109003QA (en)
TW (1) TWI845626B (en)
WO (1) WO2020180727A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
WO2017112775A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CN107474134B (en) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 Antibodies for binding interleukin-4 receptor
CN112023055A (en) * 2020-09-14 2020-12-04 南通大学 Application of IL-6R inhibitor and IL-4R inhibitor combined medicine in breast cancer chemotherapy medicine

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
IL147972A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Ge Pd-1, a receptor for b7-4 and uses therefor
DE16192152T1 (en) 2000-05-26 2020-08-06 Immunex Corporation USE OF INTERLEUKIN-4 RECEPTOR (IL-4R) ANTIBODIES AND COMPOSITIONS THEREOF
DE10161767T1 (en) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotentiating compositions containing an anti-PD-L1 antibody
ATE514713T1 (en) 2002-12-23 2011-07-15 Wyeth Llc ANTIBODIES TO PD-1 AND THEIR USE
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
CN104013957B (en) 2003-12-23 2016-06-29 泰勒公司 With new anti-il 13 antibodies for treating cancer
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AR050044A1 (en) 2004-08-03 2006-09-20 Novartis Ag IL-4 SPECIFIC ANTIBODY
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
KR20080049113A (en) 2005-10-21 2008-06-03 노파르티스 아게 Human antibodies against il-13 and therapeutic uses
CA2646626A1 (en) 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
ES2902063T3 (en) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Interleukin-13 binding proteins
DK2769992T3 (en) 2006-10-02 2021-03-22 Regeneron Pharma Human antibodies with high affinity for human IL-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
SI2350129T1 (en) 2008-08-25 2015-11-30 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
CN108997498A (en) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
PL2624865T3 (en) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
CA2814431A1 (en) 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
SI2785375T1 (en) 2011-11-28 2020-11-30 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
AR091220A1 (en) 2012-05-31 2015-01-21 Genentech Inc METHODS TO TREAT CANCER USING ANTAGONISTS OF UNION TO PD-1 AXIS AND ANTIGONISTS OF VEGF
CN115093480A (en) 2012-05-31 2022-09-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-L1
CN110624107A (en) * 2012-08-21 2019-12-31 赛诺菲生物技术公司 Methods of treating or preventing asthma by administering IL-4R antagonists
KR102130865B1 (en) * 2012-10-02 2020-08-05 브리스톨-마이어스 스큅 컴퍼니 Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2015013901A (en) 2013-04-05 2015-12-11 Genentech Inc Anti-il-4 antibodies and bispecific antibodies and uses thereof.
KR20230066127A (en) * 2013-06-21 2023-05-12 사노피 바이오테크놀로지 Methods for treating nasal polyposis by administering an il-4r antagonist
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
MY194225A (en) 2015-03-13 2022-11-22 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2017019896A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
AR105654A1 (en) 2015-08-24 2017-10-25 Lilly Co Eli ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH)
TWI756187B (en) * 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
PL3416685T3 (en) * 2016-02-19 2024-08-26 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
EP3439653B1 (en) 2016-04-07 2021-01-20 ChemoCentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI799432B (en) * 2017-07-27 2023-04-21 美商再生元醫藥公司 Anti-ctla-4 antibodies and uses thereof
WO2021062332A1 (en) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer

Also Published As

Publication number Publication date
CN113677707A (en) 2021-11-19
AU2020231343A1 (en) 2021-10-21
JP7548924B2 (en) 2024-09-10
TW202102537A (en) 2021-01-16
IL285525A (en) 2021-09-30
CA3129963A1 (en) 2020-09-10
WO2020180727A1 (en) 2020-09-10
TWI845626B (en) 2024-06-21
EP3935085A1 (en) 2022-01-12
MA55204A (en) 2022-01-12
US20200283518A1 (en) 2020-09-10
JP2022523804A (en) 2022-04-26
KR20210136071A (en) 2021-11-16
MX2021010560A (en) 2021-11-12

Similar Documents

Publication Publication Date Title
IL285525A (en) Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
IL284199A (en) Csf1r inhibitors for use in treating cancer
IL272877A (en) Shp2 inhibitor compositions and methods for treating cancer
SG11202010977QA (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
HK1245677A1 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
SG11202106627WA (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL286350A (en) Compositions and methods for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL288914A (en) Compositions and methods for treating cancer
HK1246829A1 (en) Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
IL273427A (en) Gene therapy for treating mucopolysaccharidosis type ii
SG11202106963YA (en) Methods and compositions for treating cancer
MX2017002364A (en) Combination therapy for treatment of cancer.
IL287982A (en) Compositions and methods for treating cancer
SG11202109336UA (en) Methods and compositions for treating cancer
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
GB201702160D0 (en) Inhibitors for use in therapy
IL286153A (en) Methods and compositions for treating cancer
EP3843726A4 (en) Parp inhibitors for treating cancer and asthma
IL283687A (en) Usp19 inhibitors for use in therapy
IL285036A (en) Methods and compositions for treating cancer
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
GB202405142D0 (en) Methods and compounds for treating inflammation
HUP1900281A1 (en) Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer
GB201909135D0 (en) Means and methods for treating cancer